Recommends dividend of Rs 7 per equity share
Hester Biosciences has reported a consolidated net profit of Rs 28.83 crore for the financial year ended March 2025, a rise of 36 per cent as compared to the net profit of Rs 21.17 crore reported in the financial year 2023-24. Revenue from operations of the company for the FY25 was reported at Rs. 311.10 crore, a rise of 2 per cent Y-o-Y as compared to the revenue from operations of Rs 304.55 crore. The company has recommended a dividend of Rs 7 (Seven) per equity share of Rs 10 each (70 per cent) for the financial year 2024-25, subject to the approval of members at the ensuing Annual General Meeting.
Standalone Performance: Divisional Product Sales in FY25 were up by 12 per cent and in Q4 FY25 it was up by 5 per cent. Net Profit in FY25 was up by 17 per cent and in Q4 FY25 it was up by 30 per cent.
Consolidated Performance: Divisional Product Sales in FY25 was up by 13per cent and in Q4 FY25 it was up by 3 per cent. Net Profit in FY25 up by 36 per cent and in Q4 FY25 it was down by 76 per cent.
